36 results about "Phenformin" patented technology

Disclosed is an anticancer pharmaceutical composition comprising phenformin or a pharmaceutically acceptable salt thereof, and a glycolysis inhibitor, particularly, 2-deoxy-D-glucose as active ingredients. These ingredients act in synergy with each other, thus exhibiting more potent inhibitory activity against the growth of cancer cells, compared to individual ingredients. Also, the synergistic anticancer activity allows the individual drugs to be used in lower amounts, which leads to a reduction in the occurrence of adverse effects. In addition, the time-lag release or administration of the ingredients decreases blood lactic acid levels to significantly mitigate the adverse effect of lactic acidosis, as well as exerting high anticancer effects. Particularly, the pharmaceutical composition can be formulated to dosage forms effective for therapy, increasing the drug compliance of the subject.

Disclosed is an anticancer pharmaceutical composition comprising phenformin or a pharmaceutically acceptable salt thereof, and 2-deoxy-D-glucose as active ingredients. These ingredients act in synergy with each other, thus exhibiting more potent inhibitory activity against the growth of cancer cells, compared to individual ingredients. Also, the synergistic anticancer activity allows the individual drugs to be used in lower amounts, which leads to a reduction in the occurrence of adverse effects. In addition, the time-lag release or administration of the ingredients decreases blood lactic acid levels to significantly mitigate the adverse effect of lactic acidosis, as well as exerting high anticancer effects. Particularly, the pharmaceutical composition can be formulated to dosage forms effective for therapy, increasing the drug compliance of the subject.

A pharmaceutical composition or kit of parts comprising at least three ingredients from a HMG-CoA reductase inhibitor, a leukotriene antagonist, a proton pump inhibitor, melatonin or a melatonin receptor agonist, a bioavailable preparation of a curcuminoid, a calciferol derivative, a compound from the group consisting of metformin and phenformin, valproate, minocycline and chloroquine and one or more pharmaceutically acceptable carriers or excipients.

The invention discloses a compound Chinese patent medicine which is prepared by combining Chinese medicines and western medicines, in particular to a medicine used for treating diabetes mellitus. The medicine takes the western medicines with the function of lowering blood sugar and the Chinese medicines used for preventing and treating chronic complicating disease as the main ingredients, and the ingredients particularly include: 14-18g of radix astragali paste, 16-20g of radix puerariae powder, 10-14g of angelica paste, 0.1-1g of salvia miltiorrhiza paste, 1-4g of rhizoma atractylodis paste, 0.05-0.5g of glibenclamide powder and 1.25-3.75g of phenformin powder; the preparation method is as follows: high-quality medicinal materials of radix astragali, angelica, salvia miltiorrhiza and rhizoma atractylodis are selected and decocted with water for 2 times, one hour per time; the dreg is removed, and the juice is taken and stands still for 8-12 hours; after being clarified, supernatant fluid is taken and is decocted into paste; radix puerariae is pulverized and sieved by a 120 meshes fine screen to remove fibers and prepare powder; then radix astragali paste and angelica paste as well as radix puerariae powder, salvia miltiorrhiza paste and glibenclamide powder, rhizoma atractylodis paste and phenformin powder are evenly stirred respectively and prepared into dried granules which are loaded into capsules after being evenly blended. By adopting a traditional processing technique, the product of the invention contains a variety of medicine ingredients for reducing blood sugar and preventing and treating various complicating diseases, has precise prescription, long lasting drug effect, remarkable curative effect and safe and reliable performance.

The invention relates to a method for identifying a candidate agent for use in a medicament for diabetes or obesity the method comprising (i) providing a candidate inhibitor of PPM phosphatase, (ii) providing a first and a second sample comprising PPM phosphatase, (iii) contacting the candidate inhibitor with the first sample comprising PPM phosphatase, and (iv) assaying the first and second samples for PPM phosphatase activity, wherein the PPM phosphatase is selected from the group consisting of PPM1E, PPM1F, PPM1J, PPM1K, PPM1L and PPM1M, wherein if the PPM phosphatase activity is lower in the first sample than in the second sample then the candidate inhibitor is identified as a candidate agent for use in a medicament for diabetes or obesity, preferably type II diabetes. The invention also relates to the use of metformin and phenformin as inhibitors of PPM phosphatases.

The present invention relates to a pharmaceutical composition for cancer treatment containing gossypol and phenformin as active ingredients. Specifically, the combinative treatment with gossypol and phenformin was verified to have a significantly higher anticancer activity than a single treatment with gossypol and phenformin alone. Therefore, the pharmaceutical composition of the present invention containing gossypol and phenformin having a synergetic anticancer activity can be favorably used for cancer treatment.

The invention relates to a method for identifying a candidate agent for use in a medicament for diabetes or obesity said method comprising (i) providing a candidate inhibitor of PPM phosphatase, (ii) providing a first and a second sample comprising PPM phosphatase, (iii) contacting said candidate inhibitor with said first sample comprising PPM phosphatase, and (iv) assaying said first and second samples for PPM phosphatase activity, wherein said PPM phosphatase is selected from the group consisting of PPM1E, PPM1F, PPM1J, PPM1K, PPM1L and PPM1M, wherein if the PPM phosphatase activity is lower in said first sample than in said second sample then said candidate inhibitor is identified as a candidate agent for use in a medicament for diabetes or obesity, preferably type II diabetes. The invention also relates to the use of metformin and phenformin as inhibitors of PPM phosphatases.

The invention discloses a weight losing medicament which comprises phenformin in a pharmaceutical salt form, orlistat and bisacodyl, wherein an effective dosage range of the phenformin is 20mg to 200mg per day; an effective dosage range of the orlistat is 20mg to 1500mg per day; an effective dosage range of the bisacodyl is 5mg to 15mg per day. The weight losing medicament is prepared by the following steps: mixing various components uniformly, and preparing one or several dosage forms in tablets, capsules and oral liquid mixtures to be taken or sequentially taken. Due to the phenformin, orlistat, bisacodyl and medicinal carriers, the weight losing medicament has the effects of inhibiting absorption of the intestinal tract on glucose and fat in foods, reducing blood fat, accelerating metabolism of muscles, fat and other peripheral tissues on the glucose, enhancing reflective peristalsis of rectum to accelerate excrement elimination and shortening the absorption time of the intestinal tract on sugar and fat; abdominal distension, stomachache, diarrhea and other combined effect mechanisms caused by bacteria glycolysis aerogenesis increase because the residence time of sugar and fat which are not absorbed by orlistat in the intestinal tract is extremely long are avoided, so that an aim of losing weight is achieved.

The invention discloses a compound glucose-reducing preparation containing phenformin and a preparation method of the compound glucose-reducing preparation. The compound glucose-reducing preparation consists of the following components: the phenformin, water-soluble dietary fibers, vinpocetine, vitamin B1, gastric inhibitory peptide, glutamine dipeptide, benazepril, prostaglandin A1, sophorin A, beta-glucosidase, chitosan oligosaccharide, indapamide, curcumin and sodium ferulate. The compound preparation disclosed by the invention, on the basis of the combined action of various medicinal components, is capable of promoting secretion of insulin, so that the purpose of reducing glucose is achieved; the compound preparation is capable of effectively improving immunity of a patient and preventing various diabetic complications; and moreover, the compound preparation is significant in glucose-reducing effect, low in side effects and free from adverse effects on the patient in a long term of using, and the compound preparation has a broad application prospect.

The present disclosure is directed to novel phenformin derivatives, and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof. This disclosure also provides compositions and the use of such compositions in method of treating cancer, diabetes, or polycystic ovarian syndrome.

The invention discloses a western medicine compound preparation for treating diarrhea. The estern medicine compound preparation is prepared from, by weight, 5-10 parts of taurine, 8-10 parts of cysteine, 5-8 parts of methionine, 0.05-0.2 part of gliclazide, 0.05-0.1 part of phenformin, 2-5 parts of L-carnitine, 10-20 parts of piperazine ferulate, 15-20 parts of hydrochlorothiazide, 2-5 parts of imodium, 2-5 parts of chitosan, 1-5 parts of cisapride, 1-2 parts of Nuan wei shu le tablets and 0.01-0.05 part of vitamin B1. The western medicine compound preparation has a good curative effect in the aspect of treating the diarrhea, and the effective rate reaches 98%. By compounding multiple raw materials to provide synergistic effects, the effects of strengthening the spleen, harmonizing the stomach, stopping the diarrhea and strengthen the intestines can be achieved; the preparation method is simple, the treatment cost is low, the course of treatment is short, the toxic and side effects are low, and the adverse reaction is low.

The invention discloses a phenformin oral liquid fingerprint spectrum detection method and a fingerprint spectrum thereof, and belongs to the technical field of traditional Chinese medicine preparation fingerprint spectrum detection. The method comprises the following steps: preparing a mixed reference substance solution and preparing a test solution; determining a high performance liquid chromatography condition; establishing a standard fingerprint spectrum; detecting the quality of the phenformin oral liquid to be detected, and analyzing the quality of the phenformin oral liquid by combininga chemometrics analysis method, wherein the chemometrics analysis method comprises a clustering analysis method and a principal component analysis method. According to the established chemical pattern recognition method taking similarity evaluation, clustering analysis and principal component analysis as cores, quality analysis can be carried out on different batches of phenformin oral liquids from different emphasis perspectives, and a scientific evaluation method is provided for quality control of preparations of the phenformin oral liquids.

The present invention provides a pharmaceutical composition containing gossypol and phenformin, capable of exhibiting a synergistic effect in the treatment of pancreatic cancer. When gossypol and phenformin are mixed in a concentration range provided in the present invention and the mixture is applied to the treatment of pancreatic cancer, apoptotic effects on pancreatic cancer are remarkably increased because of the co-administration thereof even in a concentration range in which a significant pancreatic cancer treatment effect cannot be achieved by the administration of gossypol or phenformin alone, such that pancreatic cancer can be effectively treated. Additionally, when an anti-cancer agent is mixed in addition to gossypol and phenformin and the mixture is applied to the treatment of pancreatic cancer, apoptotic effects on cancer cells can be remarkably increased such that pancreatic cancer can be effectively treated.

The invention particularly relates to a high performance liquid chromatography-mass spectrometry combined method for simultaneously detecting 45 types of banned drugs in health-care food for people groups with three highs (high hypertension, hyperlipemia and hyperglycemia), and belongs to the technical field of detection of chemical drugs illegally added into health-care products. According to themethod, 5mmol.L<-1> of ammonium acetate liquor and acetonitrile are subjected to gradient elution on an Agilent Eclipse Plus C18 column, wherein the flow speed is 0.2mL.min<-1>; samples are ionized in the mode of positive and negative ions of electric-spray ion sources through mass spectrometry, and a multi-reaction monitor mode is applied to detection of the 45 types of chemical drugs. Three batches of positive samples from 300 batches of samples are detected in total, and detected drugs are phenformin, glibenclamide, hydrochlorothiazide and amlodipine. The high performance liquid chromatography-mass spectrometry combined method has the advantages that detection volume is high, neglected detection of the banned drugs can be avoided to a certain extent, and the method has a wide application range and a good application prospect.

The invention discloses a western medicine compound preparation for treating colitis. The western medicine compound preparation for treating colitis is prepared from the following raw materials in parts by weight: 5-10 parts of taurine, 8-10 parts of cysteine, 5-8 parts of methionine, 0.05-0.2 part of metformin, 0.05-0.1 part of phenformin, 2-5 parts of L-carnitine, 10-20 parts of piperazine ferulate, 15-20 parts of captopril, 2-5 parts of imodium, 2-5 parts of chitosan, 1-5 parts of cisapride, 1-2 parts of Nuanwei Shule Tablet and 0.01-0.05 part of vitamin B1. The western medicine compound preparation disclosed by the invention has a better effect on treating colitis, and the effective rate reaches 98%; by compounding multiple raw materials and playing synergistic effects, the effects of strengthening the spleen and stomach as well as checking diarrhea and strengthening the intestines can be achieved; and meanwhile, a preparation method is simple, the treatment cost is low, the treatment course is short, toxic and side effects are less, and adverse effects are less.

The invention belongs to the technical field of medicines, and particularly discloses a drug for treating obesity and a preparation method thereof. The drug comprises the following components in partsby weight: 80-150 parts of orlistat, 20-80 parts of phenformin, 150-300 parts of microcrystalline cellulose, 50-100 parts of crospovidone, 80-120 parts of copovidone, 15-25 parts of silicon dioxide,15-25 parts of magnesium stearate, and 25-40 parts of a film capsule agent. The drug for treating obesity has the advantages of fast effect taking speed, durable effect, no bouncing and the like, hasno toxic and side effects, is widely applicable to use by patients with genotype congenital obesity, and patients with obesity caused by later-period influences caused by environment, living style andthe like.

The present disclosure relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administer in the treatment of cancer, and more specifically, the present invention suggests anticancer agenst capable of creating a synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as said anticancer agents in the present disclosure are sorafenib, vemurafenib, irinotecan, cisplatin, paclitaxel, and doxorubicin, and each of the aforementioned anticancer agent, when co-administered as a triple-drug combination with gossypol and phenformin can provide a significant synergistic effect in terms of the effect of suppressing the proliferation of cancer and killing cancer cell, compared to each mono-drug treatment group and a dual-drug treatment group of gossypol+phenformin.